6^th Pharmacovigilance Congress September 28-30, 2016 Toronto, Ontario, Canada

will be uploaded soon

will be uploaded soon

Ray Mattingly is Professor of Pharmacology and Oncology at Wayne State University, which has the largest single campus medical school in the USA. He has been course director for medical pharmacology and therapeutics for the medical students since 2007. He is a member of the Academy of Pharmacology Educators of the American Society for Pharmacology and Experimental Therapeutics (ASPET).

Pharmacology, Oncology, medical pharmacology

Doctor of Biological Sciences, Professor In 1969 he graduated from Yerevan State University with major in biochemistry. The most important outcomes of the scientific results: He has developed and proposed methods for diagnosis and differential diagnosis of diseases, for hemoblastosis prognosis, diagnosis and therapy methods. "Petamcin-A" is a medicine created by him which is introduced in practical medicine.

proposed methods for diagnosis and differential diagnosis of diseases, for hemoblastosis prognosis, diagnosis and therapy methods. "Petamcin-A" is a medicine created by him which is introduced in practical medicine.

Aleksander Skotnicki is a proffessor and Head of the Department of Hematology, Jagiellonian University, Poland.

Multiple clinical trials phase II, III, IV: AML, ALL, CML, CLL, MM, Non-Hodgkin Lymphoma, T-cell Lymphoma, T – lymphoblastic Leukemia, DLBCL, Follicular Lymphoma, Hemophilia A, Hemophilia B, Von Willenbrand’s Disease, Refractory Anemia and Postransfusional Hemosiderosis, Invasive Aspergillosis, Immune Thrombocytopenic Purpura, Intermediate Risk Myelodysplastic Syndrome

Dr. Gamal Hussein, a Professor of Pharmacy and Director of Interprofessional Education, has completed a Doctoral of Pharmacy and two fellowships at the University of Texas and the University of California San Francisco. Dr. Hussein received the “Innovation in Teaching” award from the American Association of Colleges of Pharmacy and the “Health-Systems Practitioner” award from the National Pharmaceutical Association

research lead to the identification of therapeutic window for felbamate, topiramate, and lamotrigine as well as the identification of drug reactions/interactions such as gabapentin-felbamate drug interaction, and propofol-induced dystonia

Richard W. McCallum, MD, FACP, FRACP (Aust), FACG, is Professor of Medicine in the Division of Gastroenterology of Texas Tech University Health Sciences Center at El Paso. Dr. McCallum is the Medical Director of the Diagnostic Center for GI Motility and Functional Bowel Disorders, a referral center for patients locally, regionally, and nationally.

will upload soon

Dr Sutapa B Neogi is a public health specialist actively engaged in research and teaching at Indian Institute of Public Health- Delhi (IIPHD), Public Health Foundation of India (PHFI) as an Additional Professor. An MBBS from Nil Ratan Sircar Medical College, Calcutta and MD in Community Medicine from Post Graduate Institute of Medical education and Research (PGIMER), Chandigarh, and Diplomate of National Board (DNB) in Maternal and Child Health, she has excellent academic credentials. She has a rich experience in public health, starting a career as a resident followed by consultancy for UNICEF and currently a faculty at IIPHD. She is a part of the research team for projects supported by Government of India and developmental partners. She is a reviewer of many national and international journals.

public health

OSSAMA HUSSEIN ROSHDY is a PROFESSOR OF DERMATOLOGY AND VENEREOLOGY,ALEXANDRIA UNIVERSITUY, Egypt

will upload soon

Biochemist and molecular biologist (University of Strasbourg, France). Senior scientist with more than 20 years of experience within Novartis in three different units: DMPK (preclinical), Clinical Pharmacology (development) and lately ADME (discovery). Provides data and expert advice companywide in DMPK areas with focus on mitigation of issues related to metabolism and drug interactions. Author of 30+ peer reviewed papers with 1300+ citations.

upload soon

Dr. Michael Merz is a clinical pharmacologist by training, with his main focus on drug safety questions during the past fourteen years. He led Quintiles’ Phase 1 clinic in Freiburg, Germany, and joined Novartis Pharma as Clinical Pharmacology Expert in 1998. At Novartis, he assumed responsibility as Head of Modeling and Simulation in Clinical Pharmacology, worked as Senior Medical Safety Expert in Clinical Safety and Epidemiology, and led the Systems Toxicology Section in Preclinical Safety. He has set up the company’s liver expert team in 2008 and has been leading the group since then. In addition, Dr. Merz is the project coordinator for the European Union’s IMI SAFE-T consortium, focusing on clinical qualification of liver, kidney, and vascular safety biomarkers.

Clinical Pharmacology

Dr. Ana Maria Castejon is currently the Principal Investigator (PI) of an ongoing multidisciplinary research study about the role of glutathione in autism. As a professor in the College of Pharmacy, she has taught core courses such as Pharmacodynamics I, II, and III, Prescription Practice, Pharmaceutics II and Clinical Pharmacology. She has also coordinated the elective course “Drugs of Abuse” and developed a new elective course for the pharmacy program: “Cardiovascular Risk Factors.” Dr. castejon holds professional affiliations and leadership positions in numerous organizations, and has received prestigious awards and recognition for her many contributions to the College of Pharmacy.

Oxidative stress, dietary manipulations to increase antioxidant capacity, oxytocin regulation of neural growth, apoptosis and oxidative stress, biomarkers Cardiovascular disease: Salt sensitivity, diabetes, statins Cardiovascular Disease